Stay updated on Eribulin Combo vs. Taxane Combo in HER2+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Eribulin Combo vs. Taxane Combo in HER2+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Eribulin Combo vs. Taxane Combo in HER2+ Breast Cancer Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Revision tag updated to v3.4.2 and prior government funding notices removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T02:27:52.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A site-wide notice about government funding status and NIH Clinical Center operations has been added, and the page revision updated from v3.4.0 to v3.4.1; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2026-02-04T01:22:27.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added: Show glossary, Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and Revision: v3.4.0; removed/changed: Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2026-01-28T00:17:33.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The page shows a new revision label (Revision: v3.3.4) replacing the previous v3.3.3; no study content or critical UI changes were observed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T01:21:31.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    Added a Locations section listing Kanagawa and Osaka sites (Yokohama, Kanagawa; Osaka) and updated the page revision to v3.3.3; removed the HHS Vulnerability Disclosure and the Kanagawa/Osaka Location entries.
    Difference
    0.3%
    Check dated 2025-12-23T09:25:46.000Z thumbnail image
  7. Check
    92 days ago
    Change Detected
    Summary
    Added a note that publications are automatically filled from PubMed and may not all be about the study, and added Revision: v3.3.2. Removed the previous PubMed publications description indicating the list is auto-generated by ClinicalTrials.gov Identifier (NCT Number) and removed Revision: v3.2.0.
    Difference
    0.1%
    Check dated 2025-11-24T17:02:58.000Z thumbnail image

Stay in the know with updates to Eribulin Combo vs. Taxane Combo in HER2+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Eribulin Combo vs. Taxane Combo in HER2+ Breast Cancer Clinical Trial page.